Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Citi
US Army
Accenture
Federal Trade Commission
Cerilliant
Baxter
Teva
Mallinckrodt

Generated: May 28, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,582,621

« Back to Dashboard

Which drugs does patent 7,582,621 protect, and when does it expire?

Patent 7,582,621 protects KERYDIN and is included in one NDA.

This patent has sixty-four patent family members in twenty countries.
Summary for Patent: 7,582,621
Title:Boron-containing small molecules
Abstract: This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.
Inventor(s): Baker; Stephen J. (Mountain View, CA), Akama; Tsutomu (Sunnyvale, CA), Bellinger-Kawahara; Carolyn (Redwood City, CA), Hernandez; Vincent S. (Watsonville, CA), Hold; Karin M. (Belmont, CA), Leyden; James J. (Malvern, PA), Maples; Kirk R. (San Jose, CA), Plattner; Jacob J. (Berkeley, CA), Sanders; Virginia (San Francisco, CA), Zhang; Yong-Kang (San Jose, CA)
Assignee: Anacor Pharmaceuticals, Inc. (Palo Alto, CA)
Application Number:11/357,687
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,582,621
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,582,621

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Anacor Pharms Inc KERYDIN tavaborole SOLUTION;TOPICAL 204427-001 Jul 7, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT FOR ONYCHOMYCOSIS THAT IS TINEA UNGUIUM ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,582,621

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,572,823 Boron-containing small molecules ➤ Sign Up
8,115,026 Boron-containing small molecules ➤ Sign Up
7,767,657 Boron-containing small molecules ➤ Sign Up
9,566,290 Boron-containing small molecules ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Fuji
Express Scripts
Healthtrust
Fish and Richardson
UBS
Teva
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.